Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data.
administrative claims data
chronic treatment
cystic fibrosis
medication adherence
prescription data
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
04
2019
accepted:
20
07
2019
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
1
10
2019
Statut:
epublish
Résumé
Cystic fibrosis (CF) is a life-shortening genetic condition that usually affects several organs and involves significant treatment burden. Adherence to medication is important for successful CF management. To describe medication adherence according to age, therapeutic class, and pharmaceutical form in adults and children followed in four regional CF centers in France. We conducted a cross-sectional study with non-transplanted patients followed in two adult and two pediatric centers during 2015 who were covered by the French National Health Insurance (NHI). Sociodemographic, clinical, hospitalization, and prescription data were collected from patient medical records. Medication dispensations were extracted from the regional French NHI database. Adherence was calculated over 12 months using continuous medication availability (CMA) accounting for dose adjustments and hospitalizations. Drug-specific CMA was computed in R with the AdhereR package for each medication prescribed more than 3 months, which was averaged to obtain a composite CMA score (cCMA) for all treatments and per therapeutic class as well as pharmaceutical form for each patient. A total of 228 patients were included. The number of chronic medications increased with age ( This study suggests that adherence to medication regimens in CF patients remains suboptimal and varies substantially between age groups and pharmaceutical forms. These variations in adherence should be considered when developing effective strategies to improve adherence.
Sections du résumé
BACKGROUND
BACKGROUND
Cystic fibrosis (CF) is a life-shortening genetic condition that usually affects several organs and involves significant treatment burden. Adherence to medication is important for successful CF management.
OBJECTIVE
OBJECTIVE
To describe medication adherence according to age, therapeutic class, and pharmaceutical form in adults and children followed in four regional CF centers in France.
METHODS
METHODS
We conducted a cross-sectional study with non-transplanted patients followed in two adult and two pediatric centers during 2015 who were covered by the French National Health Insurance (NHI). Sociodemographic, clinical, hospitalization, and prescription data were collected from patient medical records. Medication dispensations were extracted from the regional French NHI database. Adherence was calculated over 12 months using continuous medication availability (CMA) accounting for dose adjustments and hospitalizations. Drug-specific CMA was computed in R with the AdhereR package for each medication prescribed more than 3 months, which was averaged to obtain a composite CMA score (cCMA) for all treatments and per therapeutic class as well as pharmaceutical form for each patient.
RESULTS
RESULTS
A total of 228 patients were included. The number of chronic medications increased with age (
CONCLUSION
CONCLUSIONS
This study suggests that adherence to medication regimens in CF patients remains suboptimal and varies substantially between age groups and pharmaceutical forms. These variations in adherence should be considered when developing effective strategies to improve adherence.
Identifiants
pubmed: 31564837
doi: 10.2147/PPA.S211769
pii: 211769
pmc: PMC6732572
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1497-1510Informations de copyright
© 2019 Rouzé et al.
Déclaration de conflit d'intérêts
Alexandra Lelia Dima report grants and non-financial support from Respiratory Effectiveness Group, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
BMC Health Serv Res. 2012 Jun 12;12:155
pubmed: 22691240
PLoS One. 2017 Apr 26;12(4):e0174426
pubmed: 28445530
J R Soc Med. 2000;93 Suppl 38:2-8
pubmed: 10911812
Presse Med. 2017 Jun;46(6 Pt 2):e125-e138
pubmed: 28554721
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
J Cyst Fibros. 2011 Jul;10(4):258-64
pubmed: 21458391
Respir Care. 2014 Nov;59(11):1731-46
pubmed: 25233386
Lancet. 2016 Nov 19;388(10059):2519-2531
pubmed: 27140670
Pediatrics. 2016 Feb;137(2):e20152296
pubmed: 26738883
Respirology. 2014 Nov;19(8):1209-14
pubmed: 25208592
J Cyst Fibros. 2014 Dec;13(6):692-8
pubmed: 24815094
Chest. 2014 Jul;146(1):142-151
pubmed: 24480974
Health Educ Behav. 2018 Jun;45(3):435-443
pubmed: 29025281
J Cyst Fibros. 2015 Sep;14(5):621-6
pubmed: 26074007
J Bras Pneumol. 2016 Jan-Feb;42(1):29-34
pubmed: 26982038
Respir Med. 2018 May;138:88-94
pubmed: 29724399
J Cyst Fibros. 2006 Aug;5(3):177-85
pubmed: 16679071
Eur Respir J. 2017 Mar 8;49(3):
pubmed: 28275171
J Med Econ. 2013;16(6):801-8
pubmed: 23506540
J Cyst Fibros. 2009 Mar;8(2):91-6
pubmed: 18952504
Patient Prefer Adherence. 2017 Mar 30;11:691-698
pubmed: 28408806
J Paediatr Child Health. 2017 May;53(5):488-493
pubmed: 28186386
J Aerosol Med Pulm Drug Deliv. 2012 Dec;25(6):307-9
pubmed: 22856641
BMC Pulm Med. 2011 Jan 20;11:5
pubmed: 21251275
Expert Rev Respir Med. 2017 Feb;11(2):129-145
pubmed: 28107795
J Cyst Fibros. 2013 Sep;12(5):440-4
pubmed: 23369661
Pediatr Pulmonol. 2010 May;45(5):450-8
pubmed: 20425852
Eur Respir J. 2011 Dec;38(6):1328-35
pubmed: 21737560
Presse Med. 2017 Jun;46(6 Pt 2):e139-e164
pubmed: 28576636
Rev Epidemiol Sante Publique. 2004 Apr;52(2):113-7
pubmed: 15138390
Value Health. 2019 Feb;22(2):139-156
pubmed: 30711058
Chest. 2011 Aug;140(2):425-432
pubmed: 21330381
Curr Opin Pulm Med. 2013 Nov;19(6):687-91
pubmed: 24060982
Cochrane Database Syst Rev. 2017 Dec 19;12:CD012102
pubmed: 29253920